ES2870920T3 - Inhibidores de CXCR4 y usos de los mismos - Google Patents
Inhibidores de CXCR4 y usos de los mismos Download PDFInfo
- Publication number
- ES2870920T3 ES2870920T3 ES17816163T ES17816163T ES2870920T3 ES 2870920 T3 ES2870920 T3 ES 2870920T3 ES 17816163 T ES17816163 T ES 17816163T ES 17816163 T ES17816163 T ES 17816163T ES 2870920 T3 ES2870920 T3 ES 2870920T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- optionally substituted
- membered
- nitrogen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(CC*1)N1C(CC)C1C*CC1 Chemical compound CCCC(CC*1)N1C(CC)C1C*CC1 0.000 description 16
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N CCOC(C(CBr)=O)=O Chemical compound CCOC(C(CBr)=O)=O VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- UMRZSTCPUPJPOJ-UHFFFAOYSA-N C(C1)C2CC1CC2 Chemical compound C(C1)C2CC1CC2 UMRZSTCPUPJPOJ-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N C(C1)C2CCN1CC2 Chemical compound C(C1)C2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- ASUQYWCXZRNVRW-UHFFFAOYSA-N C(C1)C2CCNC1C2 Chemical compound C(C1)C2CCNC1C2 ASUQYWCXZRNVRW-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N C(C1)C2CNC1C2 Chemical compound C(C1)C2CNC1C2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N C(C1)C2CNC1CC2 Chemical compound C(C1)C2CNC1CC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- GMOFDANHMUHNBP-UHFFFAOYSA-N C(C1)C2CSC1CC2 Chemical compound C(C1)C2CSC1CC2 GMOFDANHMUHNBP-UHFFFAOYSA-N 0.000 description 1
- SNZSSCZJMVIOCR-UHFFFAOYSA-N C(C1)C2NC1CC2 Chemical compound C(C1)C2NC1CC2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N C(C1)C2NC1CNC2 Chemical compound C(C1)C2NC1CNC2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N C(C1)C2NC1COC2 Chemical compound C(C1)C2NC1COC2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N C(C1)C2OC1CNC2 Chemical compound C(C1)C2OC1CNC2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- NKFZUGIEJYGXMY-UHFFFAOYSA-N C(C1)C2OC1OC2 Chemical compound C(C1)C2OC1OC2 NKFZUGIEJYGXMY-UHFFFAOYSA-N 0.000 description 1
- PGRMVFYQFHCNSA-UHFFFAOYSA-N C(C1)C2OCCN1C2 Chemical compound C(C1)C2OCCN1C2 PGRMVFYQFHCNSA-UHFFFAOYSA-N 0.000 description 1
- ORCQJRXQASSNAQ-UHFFFAOYSA-N C(C1)C2c3ccccc3C1CC2 Chemical compound C(C1)C2c3ccccc3C1CC2 ORCQJRXQASSNAQ-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N C(C1)CN2C1CNCC2 Chemical compound C(C1)CN2C1CNCC2 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- VLCAUFUDKLGTBG-UHFFFAOYSA-N C(C12)=CC=CC1=C1OC=C2C=C1 Chemical compound C(C12)=CC=CC1=C1OC=C2C=C1 VLCAUFUDKLGTBG-UHFFFAOYSA-N 0.000 description 1
- YVPKKTHVFYAAQN-UHFFFAOYSA-N C1=CN=[I]N=C1 Chemical compound C1=CN=[I]N=C1 YVPKKTHVFYAAQN-UHFFFAOYSA-N 0.000 description 1
- WFKDDADPNCMDCZ-UHFFFAOYSA-N C1C(C=C2)=COC2=C1 Chemical compound C1C(C=C2)=COC2=C1 WFKDDADPNCMDCZ-UHFFFAOYSA-N 0.000 description 1
- YVHBSYTYLQYTOU-UHFFFAOYSA-N C1C2NC1CNC2 Chemical compound C1C2NC1CNC2 YVHBSYTYLQYTOU-UHFFFAOYSA-N 0.000 description 1
- UKHJNJFJCGBKSF-UHFFFAOYSA-N C1C2NCC1NC2 Chemical compound C1C2NCC1NC2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N C1C2OCC1NC2 Chemical compound C1C2OCC1NC2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VJKNAEZWNVUHAF-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl VJKNAEZWNVUHAF-VQTJNVASSA-N 0.000 description 1
- CTKHJJPOGHSDRV-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F CTKHJJPOGHSDRV-VQTJNVASSA-N 0.000 description 1
- ZFJYNKPPNRBFTH-FCHUYYIVSA-N CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 Chemical compound CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 ZFJYNKPPNRBFTH-FCHUYYIVSA-N 0.000 description 1
- SIZPIHICIYHVJQ-PKTZIBPZSA-N CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 Chemical compound CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 SIZPIHICIYHVJQ-PKTZIBPZSA-N 0.000 description 1
- KOMFSHQSMBSMKX-PKTZIBPZSA-N CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 KOMFSHQSMBSMKX-PKTZIBPZSA-N 0.000 description 1
- ASIBQPPRHGMYRV-UHFFFAOYSA-N CC(CC=C1)NC1=N Chemical compound CC(CC=C1)NC1=N ASIBQPPRHGMYRV-UHFFFAOYSA-N 0.000 description 1
- HXVSCNSWQUNVQU-NRRUETGQSA-N CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 Chemical compound CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 HXVSCNSWQUNVQU-NRRUETGQSA-N 0.000 description 1
- RMTXSHIMDOGRNW-QFXXITGJSA-N CC/C=N/C/C=C/C Chemical compound CC/C=N/C/C=C/C RMTXSHIMDOGRNW-QFXXITGJSA-N 0.000 description 1
- PIPWSBOFSUJCCO-UHFFFAOYSA-N CC1(C)NCCNC1 Chemical compound CC1(C)NCCNC1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
- DWARBTVEMLZQCW-SAOADBDPSA-N CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 Chemical compound CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 DWARBTVEMLZQCW-SAOADBDPSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N CC1NCCNC1 Chemical compound CC1NCCNC1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- MHASERYOVSJGAR-RBUKOAKNSA-N CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl MHASERYOVSJGAR-RBUKOAKNSA-N 0.000 description 1
- RFPBBQHDUGKCKW-LOSJGSFVSA-N CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 Chemical compound CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 RFPBBQHDUGKCKW-LOSJGSFVSA-N 0.000 description 1
- OBARYTISHKVXKC-UHFFFAOYSA-N CCNCCNCCCCC(C)(C)C Chemical compound CCNCCNCCCCC(C)(C)C OBARYTISHKVXKC-UHFFFAOYSA-N 0.000 description 1
- BJTUQUWXNCMQGA-UHFFFAOYSA-N CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O Chemical compound CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O BJTUQUWXNCMQGA-UHFFFAOYSA-N 0.000 description 1
- VJMNOJHFYDPFKP-UHFFFAOYSA-N CCOC(c1c[n]2c(Br)cccc2n1)=O Chemical compound CCOC(c1c[n]2c(Br)cccc2n1)=O VJMNOJHFYDPFKP-UHFFFAOYSA-N 0.000 description 1
- KDXGNSFLTHLKHA-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 KDXGNSFLTHLKHA-BJKOFHAPSA-N 0.000 description 1
- KXPSPKWWKRKKSH-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 KXPSPKWWKRKKSH-BJKOFHAPSA-N 0.000 description 1
- QLXRANTXWNPMIO-ZYKFHVCXSA-N CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 QLXRANTXWNPMIO-ZYKFHVCXSA-N 0.000 description 1
- KCZBSPPSZWKMOE-VQTJNVASSA-N CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl KCZBSPPSZWKMOE-VQTJNVASSA-N 0.000 description 1
- NRQSICPUUTWMEP-VQTJNVASSA-N CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 NRQSICPUUTWMEP-VQTJNVASSA-N 0.000 description 1
- QSPATAVPZRFHKY-ZWKOTPCHSA-N CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F Chemical compound CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F QSPATAVPZRFHKY-ZWKOTPCHSA-N 0.000 description 1
- QRHFTFJGHOVZHY-VQTJNVASSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 QRHFTFJGHOVZHY-VQTJNVASSA-N 0.000 description 1
- HTKVSXNFPSPXKF-ZWKOTPCHSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 HTKVSXNFPSPXKF-ZWKOTPCHSA-N 0.000 description 1
- JSYZRETYSXDPFW-ZYKFHVCXSA-N CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 JSYZRETYSXDPFW-ZYKFHVCXSA-N 0.000 description 1
- GGACZVMYUPYTQX-GFULKKFKSA-N Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 Chemical compound Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 GGACZVMYUPYTQX-GFULKKFKSA-N 0.000 description 1
- JPLKJAFZEDVAAE-UHFFFAOYSA-N Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 Chemical compound Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 JPLKJAFZEDVAAE-UHFFFAOYSA-N 0.000 description 1
- DZYAFPAMOAKYQL-MOPGFXCFSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 DZYAFPAMOAKYQL-MOPGFXCFSA-N 0.000 description 1
- XCHCGSNKJCUYBM-LEWJYISDSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 XCHCGSNKJCUYBM-LEWJYISDSA-N 0.000 description 1
- PGLOSMWHIGEBJH-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 PGLOSMWHIGEBJH-PKTZIBPZSA-N 0.000 description 1
- URBDHSGAUQCNMX-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 URBDHSGAUQCNMX-PKTZIBPZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-DFIYOIEZSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-DFIYOIEZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-WZOHSFFVSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-WZOHSFFVSA-N 0.000 description 1
- RKGVLRIDAMKDLF-UHFFFAOYSA-N Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 Chemical compound Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 RKGVLRIDAMKDLF-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N FC1(CCNCC1)F Chemical compound FC1(CCNCC1)F MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N Nc1nc(Br)ccc1 Chemical compound Nc1nc(Br)ccc1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352820P | 2016-06-21 | 2016-06-21 | |
| US201762456526P | 2017-02-08 | 2017-02-08 | |
| PCT/US2017/038609 WO2017223239A1 (en) | 2016-06-21 | 2017-06-21 | Cxcr4 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2870920T3 true ES2870920T3 (es) | 2021-10-28 |
Family
ID=60783547
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17816163T Active ES2870920T3 (es) | 2016-06-21 | 2017-06-21 | Inhibidores de CXCR4 y usos de los mismos |
| ES20212271T Active ES3073807T3 (en) | 2016-06-21 | 2017-06-21 | Substituted piperidines as cxcr4-inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20212271T Active ES3073807T3 (en) | 2016-06-21 | 2017-06-21 | Substituted piperidines as cxcr4-inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10759796B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3808748B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7054529B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116554168B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3027498A1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2870920T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017223239A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11497744B2 (en) | 2017-02-21 | 2022-11-15 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| EP3768256A4 (en) | 2018-03-19 | 2021-11-24 | Emory University | PAN-TROPICAL ENTRANCE INHIBITORS |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020264292A1 (en) * | 2019-06-26 | 2020-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物 |
| WO2021065898A1 (ja) | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | アゼパン誘導体 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN115515585A (zh) | 2020-03-10 | 2022-12-23 | X4 制药有限公司 | 用于治疗中性粒细胞减少症的方法 |
| WO2021263203A1 (en) * | 2020-06-26 | 2021-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2023003862A1 (en) | 2021-07-19 | 2023-01-26 | Emory University | Cxcr4 modulators and uses related thereto |
| EP4444304A4 (en) * | 2021-12-09 | 2025-12-17 | X4 Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF PRIMARY IMMUNE DISCOMFORT |
| US20250326753A1 (en) * | 2022-03-25 | 2025-10-23 | X4 Pharmaceuticals, Inc. | Dual cxcr4-btk inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
| EP4608508A1 (en) * | 2022-10-26 | 2025-09-03 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors for treatment of neurological diseases |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| WO1997009976A2 (en) | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| SK127398A3 (en) | 1996-03-22 | 1999-04-13 | Du Pont Pharm Co | Novel asymmetric synthesis of r-'alpha'-propyl-piperonyl amine and its analogs |
| IL133212A (en) | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| WO1999016747A1 (en) | 1997-09-30 | 1999-04-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| GB9726229D0 (en) | 1997-12-12 | 1998-02-11 | Zeneca Ltd | Resolution of chiral amines |
| WO1999032100A2 (en) | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| US6607799B1 (en) | 1998-10-15 | 2003-08-19 | 3M Innovative Properties Company | Surgical dressing with delivery system and method of manufacture |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| IL145401A0 (en) | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| MXPA02004555A (es) | 1999-11-08 | 2004-09-10 | Wyeth Corp | Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central. |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR20030034184A (ko) | 2000-09-15 | 2003-05-01 | 아노르메드 인코포레이티드 | 케모킨 수용체 결합 헤테로사이클릭 화합물 |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| RU2289581C2 (ru) | 2000-09-15 | 2006-12-20 | Анормед, Инк. | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| CN102302493B (zh) | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | 活化祖细胞/干细胞的方法 |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| EP1487795B1 (en) | 2001-09-12 | 2010-11-03 | Anormed Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| CA2467718C (en) | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7491544B2 (en) | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| CA2520259A1 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| RU2005136224A (ru) | 2003-04-22 | 2006-06-10 | Анормед Инк. (Ca) | Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7332605B2 (en) | 2004-03-15 | 2008-02-19 | Anormed, Inc. | Process for the synthesis of CXCR4 antagonist |
| AU2005233632A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TW200612935A (en) | 2004-08-02 | 2006-05-01 | Smithkline Beecham Corp | Chemical compounds |
| PE20060646A1 (es) | 2004-08-16 | 2006-08-04 | Smithkline Beecham Corp | Derivados de bencimidazol como moduladores de la actividad de quimioquinas |
| EP1799671A4 (en) | 2004-09-02 | 2009-06-10 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| WO2006036816A2 (en) | 2004-09-24 | 2006-04-06 | Smithkline Beecham Corporation | Chemical compounds |
| TW200619206A (en) | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006096444A2 (en) | 2005-03-04 | 2006-09-14 | Smithkline Beecham Corporation | Chemical compounds |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007006408A2 (en) | 2005-07-08 | 2007-01-18 | Bayer Healthcare Ag | Methods and kits for predicting and monitoring direct response to cancer therapy |
| US20080214562A1 (en) | 2005-07-11 | 2008-09-04 | Kristjan Gudmundsson | Chemical Compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| JP5535480B2 (ja) | 2005-08-02 | 2014-07-02 | イネオス ユーロープ リミテッド | ジエン重合 |
| US20070043012A1 (en) | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| US20080234318A1 (en) | 2005-08-31 | 2008-09-25 | Kristjan Gudmundsson | Chemical Compounds |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| JP2009517474A (ja) | 2005-11-30 | 2009-04-30 | シェーリング コーポレイション | Ccr5拮抗剤およびcxcr4拮抗剤の組み合わせを含む組成物 |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AR059197A1 (es) | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| WO2007087548A2 (en) * | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
| GB0605786D0 (en) | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| KR20090013827A (ko) | 2006-06-12 | 2009-02-05 | 화이자 프로덕츠 인크. | Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| WO2008141239A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| WO2009026251A1 (en) | 2007-08-17 | 2009-02-26 | The General Hospital Corporation | Detecting ions and measuring ion concentrations |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| EP2234487A4 (en) | 2007-12-19 | 2011-09-07 | Scripps Research Inst | ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| KR20110014141A (ko) | 2008-03-20 | 2011-02-10 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
| KR20110005819A (ko) | 2008-03-28 | 2011-01-19 | 알티리스 쎄라퓨틱스 | 케모카인 수용체 조절제 |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2010016628A (ja) | 2008-07-03 | 2010-01-21 | Canon Inc | 画像処理装置及び画像処理方法 |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| US9119790B2 (en) | 2009-09-28 | 2015-09-01 | Zenbury International Limited | Pharmaceutical composition |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20110295365A1 (en) | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| CA2706292A1 (en) | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| AU2011336397B2 (en) | 2010-12-03 | 2016-12-15 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| EP2648754A4 (en) * | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHOD OF INHIBITING CANCER METASTASES |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2821985C (en) | 2011-01-11 | 2019-07-09 | Dimerix Bioscience Pty Ltd | Combination therapy |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| CN103814024B (zh) | 2011-09-26 | 2016-11-23 | 默克专利股份公司 | 作为溶血磷脂酸(lpa)受体拮抗剂的苄基哌啶化合物 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2860995A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| CA2892490A1 (en) | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| HK1219044A1 (zh) * | 2013-03-15 | 2017-03-24 | 艾伯维德国有限责任两合公司 | 抗egfr抗体药物偶联物制剂 |
| BR112015030518A2 (pt) | 2013-06-05 | 2017-08-29 | Salk Inst For Biological Studi | Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12) |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| US10280183B2 (en) | 2014-03-18 | 2019-05-07 | The Research Foundation For The State University Of New York | Therapeutic agent for treating tumors |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| KR20170105514A (ko) | 2014-12-12 | 2017-09-19 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | 알파 9 인테그린 길항제 및 cxcr4 길항제를 사용한 hsc의 이탈 및 방출 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10379661B2 (en) | 2015-09-25 | 2019-08-13 | Samsung Electronics Co., Ltd. | Coordinate measuring apparatus and coordinate measuring system having the same |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| EP3405203A4 (en) | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3443013B1 (en) | 2016-04-14 | 2025-01-22 | Creatv Microtech, Inc. | Methods of using pd-l1 expression in treatment decisions for cancer therapy |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
| CA3066778A1 (en) | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP2021502071A (ja) | 2017-11-07 | 2021-01-28 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がんバイオマーカーおよびその使用方法 |
| CA3085763A1 (en) | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| JP2021521439A (ja) | 2018-04-13 | 2021-08-26 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
-
2017
- 2017-06-21 EP EP20212271.9A patent/EP3808748B1/en active Active
- 2017-06-21 CN CN202310296466.XA patent/CN116554168B/zh active Active
- 2017-06-21 ES ES17816163T patent/ES2870920T3/es active Active
- 2017-06-21 CA CA3027498A patent/CA3027498A1/en active Pending
- 2017-06-21 JP JP2018566969A patent/JP7054529B2/ja active Active
- 2017-06-21 ES ES20212271T patent/ES3073807T3/es active Active
- 2017-06-21 CN CN201780048803.6A patent/CN109562106B/zh active Active
- 2017-06-21 WO PCT/US2017/038609 patent/WO2017223239A1/en not_active Ceased
- 2017-06-21 US US16/311,020 patent/US10759796B2/en active Active
- 2017-06-21 EP EP17816163.4A patent/EP3471727B1/en active Active
-
2020
- 2020-07-27 US US16/939,723 patent/US11306088B2/en active Active
-
2022
- 2022-03-14 US US17/654,722 patent/US11780837B2/en active Active
- 2022-03-28 JP JP2022051875A patent/JP7402549B2/ja active Active
-
2023
- 2023-09-12 US US18/465,823 patent/US20240150350A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200123150A1 (en) | 2020-04-23 |
| US10759796B2 (en) | 2020-09-01 |
| EP3471727A1 (en) | 2019-04-24 |
| EP3808748B1 (en) | 2026-05-20 |
| JP7054529B2 (ja) | 2022-04-14 |
| JP2022076020A (ja) | 2022-05-18 |
| CN116554168A (zh) | 2023-08-08 |
| CA3027498A1 (en) | 2017-12-28 |
| EP3471727A4 (en) | 2019-10-09 |
| US20220372032A1 (en) | 2022-11-24 |
| JP7402549B2 (ja) | 2023-12-21 |
| US11780837B2 (en) | 2023-10-10 |
| CN109562106A (zh) | 2019-04-02 |
| EP3471727B1 (en) | 2020-12-09 |
| WO2017223239A1 (en) | 2017-12-28 |
| CN109562106B (zh) | 2023-03-21 |
| EP3808748C0 (en) | 2026-05-20 |
| US20210047320A1 (en) | 2021-02-18 |
| JP2019518767A (ja) | 2019-07-04 |
| US11306088B2 (en) | 2022-04-19 |
| ES3073807T3 (en) | 2026-07-15 |
| CN116554168B (zh) | 2025-09-23 |
| US20240150350A1 (en) | 2024-05-09 |
| EP3808748A1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7402549B2 (ja) | Cxcr4阻害剤およびその使用 | |
| JP6994767B2 (ja) | Cxcr4阻害剤およびその使用 | |
| JP7084624B2 (ja) | Cxcr4阻害剤およびその使用 | |
| EP4323066A1 (en) | Mek inhibitors and uses thereof | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
| ES2987356T3 (es) | Compuestos antiproliferación y usos de los mismos | |
| WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
| EP3990456A1 (en) | Cxcr4 inhibitors and uses thereof | |
| HK40050670A (en) | Substituted piperidines as cxcr4-inhibitors | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof | |
| EA047483B1 (ru) | Ингибиторы tead и их применения |